
|Articles|November 6, 2015
What patients tweet about their eye doctors
A few months ago, we went over to Twitter and searched both “eye doctor” and “optometrist” just to see what people were saying. We had so much fun the first time that we thought we’d do it again.
Advertisement
A few months ago, we went over to Twitter and searched both “eye doctor” and “optometrist” just to see what people were saying. The results were so funny that we just had to share them (
We had so much fun the first time that we thought we’d do it again.
Your patients tweet about everything from
Check out our latest collection of tweets from your patients.
Advertisement
Related to this article

Yuvezzi’s Health Canada submission leads this week’s recap, plus AI front desks, the EMERALD trial, and Alberta’s scope expansion.

Polygenic risk scores predicted glaucoma onset and treatment course better than family history alone in a 400,000-person biobank.

The phase 2 EMERALD trial compares 2 doses of EO2002 with placebo, with a 15-letter BCVA gain at 26 weeks as the primary end point.

The school will be admitting its inaugural Doctor of Optometry class in summer 2027, with full accreditation possible in 2030-31.

The FDA approved the Supplemental New Drug Application for phentolamine 0.75% (Ryzumvi, Opus Genetics/Viatris) to treat presbyopia.

Will AI reinvent the way patients book appointments in the next 5 years? Raphael Rostenne weighs in in the season 2 finale of The Independent Advantage.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
Tenpoint Therapeutics submits NDS for Yuvezzi presbyopia drop to Health Canada
2
High Point University optometry school earns ACOE preliminary approval
3
Polygenic risk flags patients likely to need more glaucoma treatment
4
First patient dosed in EMERALD trial of EO2002 for corneal edema
5


